These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4031118)

  • 1. Pharmacokinetics of atenolol in patients treated with chronic hemodialysis or peritoneal dialysis.
    Campese VM; Feinstein EI; Gura V; Mason WD; Massry SG
    J Clin Pharmacol; 1985; 25(5):393-5. PubMed ID: 4031118
    [No Abstract]   [Full Text] [Related]  

  • 2. Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
    Salahudeen AK; Wilkinson R; McAinsh J; Bateman DN
    Br J Clin Pharmacol; 1984 Sep; 18(3):457-60. PubMed ID: 6487486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis.
    Lee CS; Peterson JC; Marbury TC
    J Clin Pharmacol; 1983 Jul; 23(7):274-80. PubMed ID: 6886029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.
    Flouvat B; Decourt S; Aubert P; Potaux L; Domart M; Goupil A; Baglin A
    Br J Clin Pharmacol; 1980 Apr; 9(4):379-85. PubMed ID: 7378254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of peritoneal dialysis and hemodialysis on respiratory function in patients with chronic renal failure].
    Wanic-Kossowska M
    Pol Arch Med Wewn; 1991 May; 85(5):303-11. PubMed ID: 1896394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis.
    Benziger DP; Pertel PE; Donovan J; Yankelev S; Schwab RJ; Swan SK; Cannon C
    Clin Nephrol; 2011 Jan; 75(1):63-9. PubMed ID: 21176752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.
    Merdjan H; Baumelou A; Diquet B; Chick O; Singlas E
    Br J Clin Pharmacol; 1985 Feb; 19(2):211-7. PubMed ID: 3986079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Myoneuropathy in patients with chronic renal failure treated with hemodialysis (HD) and intermittent peritoneal dialysis (IPD). II. Sensory and motor nerve conduction velocity in patients with chronic renal failure treated with intermittent peritoneal dialysis and hemodialysis].
    Wanic-Kossowska M; Koczocik-Przedpelska J
    Pol Arch Med Wewn; 1996 Mar; 95(3):237-44. PubMed ID: 8755854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Doxycycline pharmacokinetics in chronic kidney failure patients treated by hemodialysis].
    Słuczanowski W
    Ann Acad Med Stetin; 1981; 27():313-30. PubMed ID: 7345952
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma levels of atenolol after haemodialysis in patients with end stage renal disease.
    Rosseel MT; Bogaert MG; Christiaens M; Verpooten GA; De Broe ME
    Arch Int Pharmacodyn Ther; 1979 May; 239(1):176. PubMed ID: 485716
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of quality of life of patients on continuous ambulatory peritoneal dialysis, hemodialysis, and after transplantation.
    Simmons RG; Anderson C; Kamstra L
    Am J Kidney Dis; 1984 Nov; 4(3):253-5. PubMed ID: 6388319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis.
    Regeur L; Colding H; Jensen H; Kampmann JP
    Antimicrob Agents Chemother; 1977 Feb; 11(2):214-8. PubMed ID: 848923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics.
    Gerig JS; Bolton ND; Swabb EA; Scheld WM; Bolton WK
    Kidney Int; 1984 Sep; 26(3):308-18. PubMed ID: 6542606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life assessments in hemodialysis and peritoneal dialysis patients: an important dimension of patient choice why is the evidence favoring hemodialysis over peritoneal dialysis misleading?
    Finkelstein AF; Wuerth D; Finkelstein SH
    Semin Dial; 2007; 20(3):211-3. PubMed ID: 17555485
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
    MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW
    Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal dialysis in renal failure associated with spinal cord injury.
    Vaziri ND; Lopez G; Nikakhtar B; Gordon S; Penera N
    J Am Paraplegia Soc; 1984 Oct; 7(4):63-5. PubMed ID: 6512526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis.
    Jaffe G; Meyers BR; Hirschman SZ
    Antimicrob Agents Chemother; 1974 Jun; 5(6):611-6. PubMed ID: 15825414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal dialysis: a temporizing means for hemodialysis patients with subdural hematomas.
    Bidwell G; Sherrard D; Mathews M
    Nephron; 1977; 18(6):352-3. PubMed ID: 876443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of peritoneal dialysis of the pharmacokinetics of amikacin.
    Matzke GR; Salem N; Bockbrader H; Blevins R
    Proc Clin Dial Transplant Forum; 1980; 10():302-4. PubMed ID: 7346850
    [No Abstract]   [Full Text] [Related]  

  • 20. Changes in copper and ceruloplasmin in chronic renal insufficiency treated by hemodialysis and peritoneal dialysis.
    Bustamante J; Martin Mateo MC; De Paula de Pedro A; Ortiz Manchado O
    Nephron; 1978; 22(4-6):312-5. PubMed ID: 740091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.